Cargando…
‘Precision medicine’ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory)
Improving cardiovascular risk assessment requires a ‘personalized’ approach. Appraisal of well-known cardiovascular risk factors should be integrated with markers of cardiovascular risk such as LDL cholesterol (C-LDL) and C-reactive protein (CRP). Results of the recent trials of PCSK9 inhibitor mono...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439940/ https://www.ncbi.nlm.nih.gov/pubmed/30948956 http://dx.doi.org/10.1093/eurheartj/suz029 |